Volume | 8,698,617 |
|
|||||
News | (1) | ||||||
Day High | 44.97 | Low High |
|||||
Day Low | 44.30 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Bristol Myers Squibb Co | BMY | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
44.75 | 44.30 | 44.97 | 44.94 | 44.74 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
79,467 | 8,698,617 | $ 44.76 | $ 389,333,839 | - | 43.333 - 69.10 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:18:09 | 1 | $ 44.55 | USD |
Bristol Myers Squibb (BMY) Options Flow Summary
Bristol Myers Squibb Co Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
90.88B | 2.02B | - | 45.01B | 8.03B | 3.97 | 11.32 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Bristol Myers Squibb News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BMY Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 43.93 | 44.97 | 43.495 | 44.06 | 10,991,644 | 0.51 | 1.16% |
1 Month | 49.04 | 49.56 | 43.333 | 45.83 | 14,280,333 | -4.60 | -9.38% |
3 Months | 49.35 | 55.035 | 43.333 | 50.07 | 15,456,839 | -4.91 | -9.95% |
6 Months | 50.61 | 55.035 | 43.333 | 50.15 | 15,475,677 | -6.17 | -12.19% |
1 Year | 68.05 | 69.10 | 43.333 | 54.27 | 13,079,142 | -23.61 | -34.70% |
3 Years | 64.64 | 81.435 | 43.333 | 63.45 | 11,577,563 | -20.20 | -31.25% |
5 Years | 46.90 | 81.435 | 41.19 | 60.95 | 12,281,355 | -2.46 | -5.25% |
Bristol Myers Squibb Description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power. |